Drug intelligence / Profile preview

123I-MNI-388

Development stage
Unknown
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

123I-MNI-388 is a radiopharmaceutical, likely intended for diagnostic imaging. The "123I" prefix indicates that it contains Iodine-123, a radioactive isotope commonly used in nuclear medicine for imaging. The "MNI-388" component refers to a specific ligand that is labeled with Iodine-123. While the precise chemical structure and biological target of the MNI-388 ligand are not publicly available, compounds with the "MNI" prefix are often developed as radioligands for imaging specific biological receptors or transporters in research and clinical settings. As a radiopharmaceutical, its mechanism involves the selective binding of the MNI-388 ligand to its target, allowing the Iodine-123 radioisotope to be localized and detected by imaging techniques such as SPECT (Single-Photon Emission Computed Tomography), thereby providing diagnostic information about the distribution and function of the target in the body.

Beyond the preview

Go deeper on 123I-MNI-388.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 123I-MNI-388.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call